Biomm Valuation
Is BIOM3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOM3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BIOM3's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BIOM3's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOM3?
Key metric: As BIOM3 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BIOM3's PS Ratio? | |
|---|---|
| PS Ratio | 9.8x |
| Sales | R$122.91m |
| Market Cap | R$1.17b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.2x |
| Enterprise Value/EBITDA | -18x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BIOM3's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17x | ||
BLAU3 Blau Farmacêutica | 1.6x | 11.7% | R$2.7b |
OFSA3 Ouro Fino Saúde Animal Participações | 1.2x | n/a | R$1.2b |
TSVT 2seventy bio | 3.8x | 21.8% | US$181.6m |
IMU Imugene | 61.4x | 58.2% | AU$304.9m |
BIOM3 Biomm | 9.8x | n/a | R$1.2b |
Price-To-Sales vs Peers: BIOM3 is good value based on its Price-To-Sales Ratio (9.8x) compared to the peer average (17x).
Price to Sales Ratio vs Industry
How does BIOM3's PS Ratio compare vs other companies in the Global Biotechs Industry?
| 283 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 283 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: BIOM3 is expensive based on its Price-To-Sales Ratio (9.8x) compared to the Global Biotechs industry average (9.2x).
Price to Sales Ratio vs Fair Ratio
What is BIOM3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 9.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BIOM3's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Novartis
CHF 183.4b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
N1VS34
CHF 60.42
7D
-1.2%
1Y
30.2%
BeiGene
US$20.1b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
B1GN34
US$45.36
7D
-4.8%
1Y
n/a
GSK
UK£53.1b
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
G1SK34
UK£40.10
7D
-4.6%
1Y
16.9%